Prevalence of Myopathy in Subjects on Statin Therapy Attending the National Center for Diabetes, Endocrinology and Genetics in JordanYazan Khlief1, Dana Hyassat1, Mohammed Liswi1, Hashem Jaddou2and Kamel Ajlouni1,*
- Corresponding Author:
- Kamel Ajlouni
National Center for Diabetes
Endocrinology and Genetics
Aman 11942, Jordan
Tel: +962 6 534 7810
Fax: +962 6 535 6670
E-mail: [email protected]
Received Date:November 02, 2015;Accepted Date:November 05, 2015;Published Date:November 09, 2015
Citation: Khlief Y, Hyassat D, Liswi M, Jaddou H, Ajlouni K (2015) Prevalence of Myopathy in Subjects on Statin Therapy Attending the National Center for Diabetes, Endocrinology and Genetics in Jordan. Endocrinol Metab Syndr 4:204. doi:10.4172/2161-1017.1000204
Copyright:© 2015 Khlief Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: This study aims to find the prevalence and risk factors of myopathy in subjects on statin therapy.
Methods: Cross sectional study was conducted on 1046 subjects on statin therapy for dyslipidemia who were attending the National center for Diabetes, Endocrinology and Genetics [NCDEG] in Jordan between Sep. and Dec. 2012. Questionnaire was used to collect demographic data, medical history and muscular symptoms.
Results: The prevalence of muscular symptoms among subjects taking statin was 27.9%, when subjects referred their muscular symptoms to statin the prevalence drop to 16.4%. Bivariate and multivariate analyses showed significant association between muscular symptoms and hypothyroidism, taking medication or substances that are known to interact with statin treatment [Fibrates, Verapamil, Amiodarone, Warfarin, Digoxin or Grapefruit juice [>1 quart/day]], and allopurinol therapy.
Conclusions: Statin use is significantly associated with high prevalence of musculoskeletal pain [27.9%]. Although many clinicians perceive myalgia as a minor adverse effect, its clinical significance should not be underestimated, as myalgia could be a major obstacle to treatment adherence.